OOIR: Observatory of International Research

Papers

(The H4-Index of Alzheimers Research & Therapy is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody	440
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering	158
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment	158
Cognitive impact of COVID-19: looking beyond the short term	146
Randomized crossover trial of a modified ketogenic diet in Alzheimer’s disease	137
Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study	123
Machine learning methods for predicting progression from mild cognitive impairment to Alzheimer’s disease dementia: a systematic review	115
A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia	111
APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer’s disease: a systematic review	110
Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment	106
Mesenchymal stem cell-derived exosome: a promising alternative in the therapy of Alzheimer’s disease	101
Loss of perivascular aquaporin-4 localization impairs glymphatic exchange and promotes amyloid β plaque formation in mice	99
Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231	97
Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach	81
The association of APOE ε4 with cognitive function over the adult life course and incidence of dementia: 20 years follow-up of the Whitehall II study	79
Multi-platform proteomic analysis of Alzheimer’s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome	77
Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals	75
Portals to frailty? Data-driven analyses detect early frailty profiles	72
Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias	69
Hormone replacement therapy is associated with improved cognition and larger brain volumes in at-risk APOE4 women: results from the European Prevention of Alzheimer’s Disease (EPAD) cohort	66
Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer’s disease dementia: a phase I clinical trial	66
Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging: a COSMIC study	65
Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer’s disease	65
Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice	65
The Alzheimer’s disease drug development landscape	63

An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer’s disease	62
Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis	60
In vivo tau pathology is associated with synaptic loss and altered synaptic function	59
Data-driven FDG-PET subtypes of Alzheimer’s disease-related neurodegeneration	58
The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review	58
Association of Aβ deposition and regional synaptic density in early Alzheimer’s disease: a PET imaging study with [11C]UCB-J	57
The accuracy and robustness of plasma biomarker models for amyloid PET positivity	57
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease	56
A comparative study of the effects of Aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 mouse model of Alzheimer disease	56
Sex differences in neuropsychiatric symptoms in Alzheimer’s disease dementia: a meta-analysis	55
Retinal microvasculature dysfunction is associated with Alzheimer’s disease and mild cognitive impairment	55
Human neural stem cell-derived extracellular vesicles mitigate hallmarks of Alzheimer’s disease	53
Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression	53
The insulin resistance by triglyceride glucose index and risk for dementia: population-based study	52
Mild behavioral impairment: measurement and clinical correlates of a novel marker of preclinical Alzheimer’s disease	51
AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer’s drug discovery	50
Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services—part 2 of 6	50
Melatonin levels in the Alzheimer’s disease continuum: a systematic review	49
GPS driving: a digital biomarker for preclinical Alzheimer disease	48
Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer’s disease	48
Health-related quality of life in people with predementia Alzheimer’s disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review	47
Associations of Alzheimer’s disease risk variants with gene expression, amyloidosis, tauopathy, and neurodegeneration	47
Early diagnosis of Alzheimer’s disease using machine learning: a multi-diagnostic, generalizable approach	47